Two steps exist because no single antibody assay is both sensitive and specific enough to stand on its own. A negative first step usually ends the process. A reactive or equivocal first step moves forward, and both tiers have to agree before a laboratory reports a positive. The rest of this guide covers what each tier does, why an early test can be falsely reassuring, what pushes a result toward a false positive, and which tests sit outside validated laboratory practice.
A Lyme lab test looks for antibodies your immune system has made against Borrelia burgdorferi, the tick-borne bacterium behind Lyme disease, rather than for the bacterium itself. Lyme borreliosis is identified from a combination of plausible tick exposure, clinical features and, in most situations, serology 1.
That indirect design explains nearly everything else about the test. Antibodies are proteins the immune system builds after it meets a pathogen. They take time to appear, they linger long after the encounter has ended, and they can sometimes bind proteins from organisms other than the one that triggered them. A serology result is a record of an immune response, not a live headcount of bacteria in your bloodstream.
There is a biological reason laboratories work this way. After transmission, the bacterium tends to stay in skin and connective tissue and to spread through tissue rather than circulating in large numbers in blood, so a blood sample contains very few organisms, and laboratory diagnosis rests mainly on antibody detection rather than on culture or on amplifying bacterial DNA from blood 2.
Two antibody classes are reported. IgM is the earlier, shorter-lived response. IgG develops later and persists for much longer. Laboratories read both because the pattern carries timing information, although, as later sections explain, IgM reactivity on its own is the least reliable part of the picture.
Laboratories run two steps because each step covers the weakness of the other. The first tier is tuned for sensitivity, the second for specificity, and the combination gives a more trustworthy answer than either alone.
The first tier is usually an enzyme immunoassay, sometimes an immunofluorescence assay. It is built to miss as few true cases as possible, which unavoidably means it also flags some samples whose antibodies are binding for unrelated reasons. On its own, it would label too many people reactive.
The second tier filters those. In standard two-tier testing, that filter is a western immunoblot read separately for IgM and IgG, where individual antibody bands against specific bacterial proteins are counted against defined interpretive criteria, commonly two of three bands on the IgM blot and five of ten on the IgG blot 2. In modified two-tier testing, the immunoblot is replaced by a second enzyme immunoassay that uses different antigens, and research suggests this arrangement performs comparably to the blot while removing the subjectivity of reading bands by eye 3.
The sequence matters. A negative first tier is reported as negative, and the second tier is not run 2. Only a positive or equivocal first tier triggers the second step. The two results are then read as one answer rather than as two independent tests, which is why a laboratory report that shows a reactive screen and a negative confirmatory step is an overall negative, not a partial positive.
The two tiers answer different questions, so comparing them directly makes the logic of the whole process clearer.
| Feature | First tier | Second tier |
|---|---|---|
| Typical assay | Enzyme immunoassay, occasionally an immunofluorescence assay | Western immunoblot read for IgM and IgG, or a second enzyme immunoassay using different antigens |
| What it is built for | Catching as many true cases as possible | Confirming that reactivity is specific to the bacterium |
| Main limitation | Antibodies from other causes can register as reactive | Band reading on a blot involves judgement, and criteria vary by laboratory |
| Usual result wording | Negative, equivocal or positive | Positive or negative for IgM and for IgG separately |
| What happens next | Negative ends testing, reactive or equivocal moves to tier two | The combined result is what the laboratory reports |
Both tiers are performed on the same blood draw in most laboratories, so a second appointment is not usually needed. The practical takeaway is that a single reactive screening value is not a result yet. Until the confirmatory step is reported, there is nothing to act on.
A test can be negative in the first days because the antibodies it measures have not been made yet. Testing immediately after a bite measures an immune response that has had no time to form.
The measurable IgM response generally takes one to two weeks to develop, and IgG several weeks longer, which is why antibody tests perform least well in early localised infection 2. Research suggests that sensitivity in the earliest stage is low enough that a negative result cannot rule out infection in someone with a compatible illness and plausible exposure 2.
This is also why the characteristic expanding skin lesion, erythema migrans, is handled as a clinical finding rather than a laboratory one. A typical rash in a person with plausible exposure supports a clinical diagnosis without waiting for serology, and testing at that point often returns negative 1. Delaying care in order to wait for a positive antibody result is the mistake this design most often causes.
The mirror image is just as important. A negative test weeks or months into a persistent illness is much more informative, because by then the immune system has had time to respond. Interpreting any negative result therefore means asking one question first, which is how much time has passed since the suspected exposure.
The right time to get tested is when there has been plausible tick exposure, symptoms that fit, and enough time for the immune system to respond, with the clear exception of a classic rash, which does not need a test to be acted on 1.
In practice, three situations come up. The first is a recent bite with no symptoms, where testing immediately adds nothing useful, because there is no immune response to detect yet 2. The second is a febrile or flu-like illness within weeks of exposure, where a test may be negative early and worth repeating on a later sample so the two can be compared. The third is a later presentation with joint, neurological or cardiac features, where serology is generally at its most informative because IgG has had time to build 2.
Paired sampling is the tool that resolves most early uncertainty. A sample taken during the acute illness and a second taken after an interval allow a laboratory to look for a change in antibody status rather than judging a single snapshot.
What testing cannot do is serve as a screening tool for people with no exposure and no compatible illness. The lower the chance of infection before the test, the higher the share of positive results that turn out to be false, which is the core reason indiscriminate testing creates confusion rather than clarity 5.
A positive two-tier result means your immune system has produced specific antibodies against the bacterium at some point, which is not the same as confirming an active infection today. The result is one input, read alongside exposure history, timing and clinical findings 1.
| Result pattern | What it may reflect | What is worth discussing with a clinician |
|---|---|---|
| First tier negative, early illness | Too little time for antibodies to form, or another cause entirely | Whether a repeat sample after an interval makes sense |
| First tier reactive, confirmatory step negative | Antibodies binding for an unrelated reason | Alternative explanations for the symptoms |
| IgM positive only, within the first weeks | An early response that has not yet matured to IgG | Whether a follow-up sample shows IgG developing |
| IgM positive only, months into an illness | A less specific pattern that is often not supported on retesting | Whether the clinical picture actually fits |
| IgG positive, compatible later-stage features | A past or ongoing encounter with the bacterium | How the result fits the examination and timeline |
Studies indicate that IgM reactivity without IgG, particularly beyond the first month of illness, is a frequent source of over-diagnosis and is best not read in isolation 2. A positive report is a reason for a conversation, not a conclusion on its own, and any decision about management belongs to a licensed provider who can examine you.
False positives come from two directions, cross-reacting antibodies and a low chance of infection in the person being tested.
Cross-reactivity happens because some bacterial proteins resemble proteins from other organisms. Antibodies produced during other spirochaetal infections, certain viral infections and some autoimmune conditions can bind the antigens used in the screening assay, which is exactly the problem the confirmatory tier exists to filter 2. This is why a reactive screen alone is never reported as a diagnosis.
The second direction is statistical and less intuitive. Any test's positive results are a mix of true and false ones, and the proportion that are false rises as the underlying likelihood of disease falls. Testing a person with no exposure history and nonspecific fatigue therefore produces a positive result that is far harder to trust than the same value in a person with a recent bite and a compatible illness 5.
There is a third, quieter contributor, which is laboratory variation. Blot interpretation differs between laboratories, and criteria are not identical everywhere, so two laboratories can read the same borderline sample differently 2. None of this makes the test unreliable. It makes the test one that has to be ordered for a reason and read in context, rather than added to a panel out of curiosity.
Yes. Antibodies, particularly IgG, can remain detectable for months to years after an infection has been dealt with, so a positive result does not establish that infection is ongoing 1.
This has a direct practical consequence. Repeating serology to check whether an infection has cleared does not work, because persisting antibodies are expected rather than a sign of failure, and serology is not used to judge response to care 2. Improvement is tracked clinically, through symptoms and examination, not through a falling antibody titre.
It also means that a person who was infected years ago, recognised it or not, can test positive now for an entirely unrelated symptom. The antibody is real, the past encounter was real, and neither explains today's fatigue. Separating those two things is one of the harder conversations in this area and one of the reasons a result should be interpreted by someone who knows your history.
Observation, meaning and next step is the useful frame. The observation is a positive IgG. The meaning is prior exposure to the bacterium at some point. The next step is a clinical assessment of whether current symptoms fit a current infection, an earlier one, or something else entirely.
Direct tests exist, but their usefulness depends heavily on which sample is used. Culture and nucleic acid amplification can detect the organism itself, yet the yield from blood is low because so few organisms circulate there, which is why direct testing on blood is not the routine approach 2.
Skin is a better target than blood. Culture or amplification from a biopsy of the characteristic rash can detect the organism, although this is rarely necessary in practice because the rash itself supports a clinical diagnosis 3. Newer direct and antigen-based approaches continue to be developed, and the practical standard in most laboratories remains two-tier serology 3.
A common question concerns the tick itself. Sending a removed tick for identification or testing may tell you what species it was and whether it carried bacteria, but it does not tell you whether transmission occurred in you, and a person's care is decided on their own exposure, symptoms and examination rather than on the tick's result.
The general rule is simple. Direct detection is most useful where the organism is actually concentrated, which is tissue rather than blood, and serology remains the backbone of laboratory diagnosis for most presentations.
A number of tests marketed directly for Lyme disease sit outside validated laboratory practice, and results from them are hard to act on safely. Unconventional diagnostic tests, including lymphocyte transformation assays, certain urine antigen tests and alternative culture methods, lack adequate validation and have not demonstrated the accuracy that would justify clinical use 6.
The risk is not only a wrong answer. A diagnosis built on an unvalidated test is associated with harm, because it can lead to prolonged or inappropriate care while the actual cause of symptoms goes unexamined 7. Symptoms such as fatigue, joint pain, poor sleep and difficulty concentrating have a wide range of explanations, and anchoring on a single unvalidated result tends to close that search prematurely 7.
This is not a reason to dismiss persistent symptoms, which are real and deserve investigation. It is a reason to prefer tests whose performance is known, so that a negative result can genuinely lower the likelihood of Lyme disease and a positive one can genuinely raise it.
If you already hold a result from a specialty laboratory, the useful move is to bring the report to a clinician and ask which assay was run, how it was validated and how the result changes the overall picture. Interpretation of any such result, and any decision that follows, belongs to a licensed provider.
Testing is reasonable when symptoms fit the known stages of the illness and there is plausible exposure to ticks in an area where they carry the bacterium.
The earliest and most recognisable feature is an expanding skin lesion at the bite site, often with mild flu-like symptoms such as fever, headache, muscle ache and fatigue. In that situation the rash is itself the finding, and serology is usually negative because antibodies have not formed yet 1.
Later features are where testing earns its place. These include facial nerve weakness, radiating nerve pain, meningitis-like headache, episodes of joint swelling that favour large joints such as the knee, and, less commonly, heart rhythm disturbance 4. By this stage, antibody testing is substantially more informative than it is in the first days 2.
What does not fit well is isolated chronic fatigue or widespread pain with no exposure history and no objective findings, where the likelihood of infection is low and a positive result is correspondingly harder to trust 5. That does not mean nothing is wrong. It means the Lyme test is unlikely to be the one that explains it, and a broader assessment is more likely to find the cause.
When specific organ systems are involved, testing extends beyond a blood antibody panel to samples taken from the affected site.
In Lyme arthritis, antibody testing is almost always strongly positive by the time joint swelling appears, and amplification of bacterial DNA from joint fluid can add information when the picture is unclear 8. Joint fluid analysis also helps separate this from other causes of a swollen knee, which matters because the management paths differ.
When the nervous system is involved, laboratories can compare antibody production in cerebrospinal fluid against the level in blood, an antibody index that indicates whether antibodies are being made inside the central nervous system rather than simply leaking in 2. That comparison is more informative than a cerebrospinal fluid antibody value read on its own 3.
Cardiac involvement is the one that deserves urgency. Lyme carditis most often presents as conduction block, which can progress quickly and may cause fainting, marked shortness of breath, chest discomfort or a very slow pulse, so an electrocardiogram is central to the assessment 9. Symptoms like those are worth discussing with a clinician promptly rather than waiting on a laboratory result, and treatment decisions belong to a licensed provider.
Other tests are worth running because the same tick exposure can transmit more than one organism, and because the symptoms that prompt Lyme testing overlap with many other causes.
Ticks that carry Borrelia burgdorferi can also carry the organisms behind human granulocytic anaplasmosis and babesiosis, and co-infection changes both the testing approach and the clinical picture 4. A complete blood count and liver enzymes are often informative in that context, because low platelet and white cell counts and raised liver enzymes are features of those co-infections 4.
Beyond infection, fatigue, aching joints and poor concentration have many ordinary explanations, from thyroid function to iron status, blood sugar regulation, kidney and liver function and vitamin D. A broad baseline panel gives a clinician somewhere else to look when Lyme testing comes back negative, which it often does. FitScript's membership is built around this kind of breadth, with 150+ biomarkers tested per year and interpretation from Atlas, FitScript's AI health advisor, although antibody testing for a specific tick-borne infection is ordered separately on clinical grounds rather than included in a routine panel.
The useful principle is that a negative Lyme test should open an investigation rather than end one.
General inflammation markers show that an inflammatory process is present somewhere, and they cannot identify its cause. C-Reactive Protein is the most widely used of these, a liver-produced protein that rises in response to inflammation of many kinds, from infection to injury to chronic metabolic stress.
FitScript's optimal range for this marker is 0 to 1 mg/L, against a typical lab reference range of 0 to 3 mg/L. That optimal range is an optimization target rather than a diagnostic cut-off, and reference ranges vary by laboratory, age and sex.
A raised value alongside a suspected tick-borne illness tells you the body is responding to something. It does not point to Lyme disease specifically, and a normal value does not rule it out. The dedicated biomarker guide covers what the marker measures and how to read a result.
It is worth talking to a clinician whenever there is an expanding rash after a possible tick bite, an unexplained febrile illness following outdoor exposure, or any of the later features involving joints, nerves or heart rhythm.
Some situations deserve prompt attention rather than a scheduled appointment. Fainting, a very slow or irregular pulse, severe shortness of breath, new facial weakness or a severe headache with neck stiffness are worth discussing with a clinician promptly. Waiting on an antibody result in those circumstances is not the right trade.
It is also worth a conversation when a result does not match how you feel, in either direction. A positive report in someone with no exposure, or a negative report in someone with a classic rash, are both situations where the laboratory number and the clinical picture need reconciling by a person, not by a reference range 1.
This article is educational and is not medical advice. Discuss your results, your symptoms and any treatment decision with a clinician or licensed provider who can assess your full history, and never ignore a result that falls outside the standard range.
Not immediately. The test measures antibodies, and those take weeks to build, so a sample drawn in the first days after a bite is likely to be negative whether or not transmission happened. If symptoms appear, a clinician may test and then repeat the test on a later sample so the two can be compared.
Usually a single blood draw. The laboratory runs a sensitive screening immunoassay first, and if that is reactive or equivocal it runs a second, more specific confirmatory step on the same sample. You generally only see the combined result, and a reactive screen with a negative confirmatory step is reported as an overall negative.
Not on its own. A positive result means your immune system has made specific antibodies at some point, which can reflect a current infection or one from years ago. A clinician reads it alongside your exposure history, your timeline and your examination before deciding what it means for you.
No. Antibodies can stay detectable for months or years after an infection has resolved, so repeating the blood test does not show whether the organism is still present. Progress is judged clinically, through symptoms and examination, by the clinician managing your care.
Identifying the tick can be interesting, but a result from the tick does not tell you whether anything was transmitted to you. Decisions about your care are based on your own exposure, your symptoms and an examination. Bring any tick result to a clinician rather than acting on it yourself.
Assays differ between laboratories, and borderline samples sit close to the line where small differences in method or in how a blot is read change the call. Timing also matters, because a sample taken weeks later can look different from an earlier one. Ask a clinician which assay each laboratory ran before assuming one is wrong.
A negative result is a reason to keep looking, not to stop. Fatigue, joint pain and difficulty concentrating have many possible causes, and a broader set of blood tests gives a clinician other places to look. Bring your symptoms and the timeline to a clinician who can plan the next step.
Many of them use methods that are not validated to the standard applied in routine laboratories, which makes the results hard to act on safely. If you already have such a report, take it to a clinician and ask what assay was used and how it changes the overall picture. A licensed provider decides what testing or care is appropriate.